News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
262,810 Results
Type
Article (14013)
Company Profile (304)
Press Release (248493)
Section
Business (79400)
Career Advice (152)
Deals (13205)
Drug Delivery (34)
Drug Development (50357)
Employer Resources (31)
FDA (5691)
Job Trends (5120)
News (144202)
Policy (10018)
Tag
Academia (901)
Alliances (21576)
Alzheimer's disease (777)
Antibody-drug conjugate (ADC) (63)
Approvals (5678)
Artificial intelligence (80)
Bankruptcy (99)
Best Places to Work (4539)
Biotechnology (249)
Breast cancer (121)
Cancer (996)
Cardiovascular disease (82)
Career advice (132)
CAR-T (82)
Cell therapy (238)
Clinical research (40319)
Collaboration (370)
Compensation (152)
COVID-19 (1013)
C-suite (98)
Cystic fibrosis (69)
Data (1044)
Diabetes (92)
Diagnostics (1214)
Earnings (29047)
Events (47374)
Executive appointments (295)
FDA (6113)
Funding (358)
Gene editing (69)
Gene therapy (179)
GLP-1 (325)
Government (1065)
Healthcare (6559)
Infectious disease (1054)
Inflammatory bowel disease (100)
IPO (7216)
Job creations (859)
Job search strategy (127)
Layoffs (191)
Legal (1376)
Lung cancer (144)
Lymphoma (63)
Manufacturing (91)
Medical device (2563)
Medtech (2564)
Mergers & acquisitions (6169)
Metabolic disorders (282)
Neuroscience (1054)
NextGen: Class of 2025 (2013)
Non-profit (850)
Northern California (1196)
Obesity (153)
Opinion (92)
Parkinson's disease (82)
Patents (68)
People (25212)
Phase I (14225)
Phase II (18744)
Phase III (11867)
Pipeline (445)
Postmarket research (851)
Preclinical (5979)
Radiopharmaceuticals (207)
Rare diseases (219)
Real estate (1411)
Regulatory (8345)
Research institute (932)
Series A (71)
Southern California (1074)
Startups (1967)
United States (9465)
Vaccines (174)
Weight loss (91)
Date
Today (10)
Last 7 days (264)
Last 30 days (1101)
Last 365 days (20401)
2025 (964)
2024 (20574)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (17009)
Australia (2871)
California (2722)
Canada (866)
China (245)
Colorado (101)
Connecticut (116)
Europe (36585)
Florida (303)
Georgia (78)
Illinois (169)
Indiana (66)
Maryland (361)
Massachusetts (2162)
Minnesota (111)
New Jersey (672)
New York (747)
North Carolina (441)
Northern California (1196)
Ohio (87)
Pennsylvania (520)
South America (207)
Southern California (1074)
Texas (304)
Washington State (266)
262,810 Results for "arrakis therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Arrakis Therapeutics Unveils Data for its Lead, Rationally Designed, RNA-Targeted Small Molecule (rSM) Drug Program Demonstrating Disease-Modifying Binding to RNA to Treat Myotonic Dystrophy
December 4, 2024
·
5 min read
Genetown
Arrakis Therapeutics to Participate in Upcoming May 2022 Investor Conferences
Arrakis Therapeutics announced that company management will participate in the following upcoming investor conferences: 2022 RBC Capital Markets Global Healthcare Conference Michael Gilman, Ph.D., Chief Executive Officer of Arrakis, will participate in a fireside chat on Tuesday, May 17, 2022 at 10:30 a.m. ET in New York.
May 10, 2022
·
1 min read
Genetown
Arrakis Therapeutics to Participate in Upcoming Investor Conferences - Mar 31, 2022
Arrakis Therapeutics announced that company management will participate in the following upcoming investor conferences: Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare Michael Gilman, Ph.D., Chief Executive Officer of Arrakis, will participate in a panel discussion on Thursday, April 7, 2022 at 11:00 a.m.
March 31, 2022
·
1 min read
Genetown
Arrakis Therapeutics to Present at Jefferies Healthcare Conference - June 01, 2022
Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, announced that Michael Gilman, Ph.D., Chief Executive Officer, will present a corporate overview at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 3:30 p.m. ET in New York.
June 1, 2022
·
1 min read
Business
Arrakis Therapeutics Appoints James Mutamba, PhD, as Chief Business Officer
Arrakis Therapeutics today announced that James Mutamba, PhD, has joined the company as Chief Business Officer.
December 6, 2021
·
3 min read
Genetown
Arrakis Therapeutics to Present at Guggenheim Healthcare Talks Oncology Conference
Arrakis Therapeutics today announced that Michael Gilman, Ph.D., Chief Executive Officer, will present a corporate overview at the Guggenheim Healthcare Talks Oncology Conference on Friday, February 11, 2022 at 10:00 a.m. ET.
February 8, 2022
·
1 min read
Business
Amgen and Arrakis Aim to Destroy Disease with Targeted RNA Degraders
Amgen will partner with Arrakis Therapeutics for an innovative collaboration to research and develop RNA degrader therapeutics.
January 11, 2022
·
2 min read
·
Alvin Clavines
Business
AMGEN AND ARRAKIS THERAPEUTICS ANNOUNCE MULTI-TARGET COLLABORATION TO IDENTIFY NOVEL RNA DEGRADER SMALL MOLECULE THERAPEUTICS
Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a range of difficult-to-drug targets in multiple therapeutic areas.
January 11, 2022
·
10 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Genetown
Arrakis Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
Arrakis Therapeutics today announced that Michael Gilman, Ph.D., Chief Executive Officer, will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 8:30 a.m. ET.
January 10, 2022
·
1 min read
1 of 26,281
Next
